Clinical and Metabolic Characterization of Lean Caucasian Subjects with Non-alcoholic Fatty Liver

American Journal of Gastroenterology

Volumn 112, Issue 1, 2017, Pages 102-110

  Feldman, Alexandra ^a   Eder, Sebastian K ^a   Felder, Thomas K ^a   Kedenko, Lyudmyla ^a   Paulweber, Bernhard ^a   Stadlmayr, Andreas ^b   Huber Schönauer, Ursula ^b   Niederseer, David ^b   Stickel, Felix ^c   Auer, Simon ^a   Haschke Becher, Elisabeth ^a   Patsch, Wolfgang ^a   Datz, Christian ^a,b   Aigner, Elmar ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; ADIPONECTIN; AMINE; BIOGENIC AMINE; LYSINE; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; TYROSINE; VALINE; ADIPONUTRIN, HUMAN; ADIPOQ PROTEIN, HUMAN; INSULIN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; ALLELE; ARTICLE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GENOTYPE; HABIT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REAL TIME ULTRASOUND SCANNER; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; AGED; CASE CONTROL STUDY; COMPLICATION; DIAGNOSTIC IMAGING; GENETICS; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADIPONECTIN; ADULT; AGED; ALLELES; BODY MASS INDEX; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPASE; LIVER; LYSINE; LYSOPHOSPHATIDYLCHOLINES; MALE; MEMBRANE PROTEINS; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PHOSPHATIDYLCHOLINES; POLYMORPHISM, SINGLE NUCLEOTIDE; TYROSINE; ULTRASONOGRAPHY; VALINE;

EID: 84982179058     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.318     Document Type: Article

References (55)

1. Pereira K, Salsamendi J, Casillas J. The global nonalcoholic fatty liver disease epidemic: what a radiologist needs to know. J Clin Imag Sci 2015; 5: 32.
2. Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin Obes 2014; 4: 243-53.
3. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
4. Das K, Chowdhury A. Lean NASH: distinctiveness and clinical implication. Hepatol Int 2013; 7 (Suppl 2): 806-13.
5. Feng RN, Du SS, Wang C et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol 2014; 20: 17932-40.
6. Whitsett M, VanWagner LB. Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review. World J Hepatol 2015; 7: 2041-52.
7. Anstee QM, Day CP. The genetics of NAFLD. Nature reviews. Gastroenterol Hepatol 2013; 10: 645-55.
8. Maximos M, Bril F, Portillo Sanchez P et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 2015; 61: 153-60.
9. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-725.e6.
10. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
11. Paradies G, Paradies V, Ruggiero FM et al. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 14205-18.
12. Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free Radic Res 2015, 1-14.
13. Tilg H, Moschen AR. Food, immunity, and the microbiome. Gastroenterology 2015; 148: 1107-19.
14. Valenti L, Al-Serri A, Daly AK et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-17.
15. Kumashiro N, Yoshimura T, Cantley JL et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology 2013; 57: 1763-72.
16. Liu YL, Reeves HL, Burt AD et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014; 5: 4309.
17. Kozlitina J, Smagris E, Stender S et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352-6.
18. Speliotes EK, Yerges-Armstrong LM, Wu J et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
19. Stadlmayr A, Aigner E, Steger B et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med 2011; 270: 41-9.
20. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
21. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
22. Roeb E, Steffen HM, Bantel H et al. [S2k Guideline non-alcoholic fatty liver disease]. Z Gastroenterol 2015; 53: 668-723.
23. Kedenko L, Lamina C, Kedenko I et al. Genetic polymorphisms at SIRT1 and FOXO1 are associated with carotid atherosclerosis in the SAPHIR cohort. BMC Med Genet 2014; 15: 112.
24. Craig CL, Marshall AL, Sjostrom M et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-95.
25. Xia J, Psychogios N, Young N et al. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res 2009; 37: W652-W660.
26. Xia J, Sinelnikov IV, Han B et al. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res 2015; 43: W251-W257.
27. Hochberg Y, Benjamini Y. More powerful procedures for multiple signifi-cance testing. Stat Med 1990; 9: 811-8.
28. Robin X, Turck N, Hainard A et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77.
29. Kwok R, Choi KC, Wong GL et al. Screening diabetic patients for nonalcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2015; 65: 1359-68.
30. Younossi ZM, Stepanova M, Negro F et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012; 91: 319-27.
31. Wong VW, Hui AY, Tsang SW et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006; 24: 1215-22.
32. Yun JW, Cho YK, Park JH et al. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int 2009; 29: 525-9.
33. Park SH, Kim BI, Yun JW et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004; 19: 694-8.
34. Sinn DH, Gwak GY, Park HN et al. Ultrasonographically detected nonalcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. A J Gastroenterol 2012; 107: 561-7.
35. Nakamuta M, Kohjima M, Higuchi N et al. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease. Int J Mol Med 2008; 22: 663-7.
36. Shen J, Wong GL, Chan HL et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 2014; 39: 532-9.
37. Mangge H, Baumgartner BG, Zelzer S et al. Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages. Aliment Pharmacol Ther 2015; 42: 99-105.
38. Hyysalo J, Gopalacharyulu P, Bian H et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes 2014; 63: 312-22.
39. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastro enterol 2011; 17: 3377-89.
40. Stommel M, Schoenborn CA. Variations in BMI and prevalence of health risks in diverse racial and ethnic populations. Obesity 2010; 18: 1821-6.
41. Kita T, Kume N, Ishii K et al. Oxidized LDL and expression of monocyte adhesion molecules. Diabetes Res Clin Pract 1999; 45: 123-6.
42. Subbaiah PV, Liu M, Bolan PJ et al. Altered positional specificity of human plasma lecithin-cholesterol acyltransferase in the presence of sn-2 arachidonoyl phosphatidyl cholines. Mechanism of formation of saturated cholesteryl esters. Biochim Biophys Acta 1992; 1128: 83-92.
43. Heimerl S, Fischer M, Baessler A et al. Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PLoS One 2014; 9: e111348.
44. Lee SY, Kim M, Jung S et al. Altered plasma lysophosphatidylcholines and amides in non-obese and non-diabetic subjects with borderline-to-moderate hypertriglyceridemia: a case-control study. PLoS One 2015; 10: e0123306.
45. Hung ND, Kim MR, Sok DE. 2-Polyunsaturated acyl lysophosphatidylethanolamine attenuates inflammatory response in zymosan A-induced peritonitis in mice. Lipids 2011; 46: 893-906.
46. Hung ND, Kim MR, Sok DE. Mechanisms for anti-inflammatory effects of 1-[15(S)-hydroxyeicosapentaenoyl] lysophosphatidylcholine, administered intraperitoneally, in zymosan A-induced peritonitis. Br J Pharmacol 2011; 162: 1119-35.
47. Soga T, Ohishi T, Matsui T et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005; 326: 744-51.
48. Mihalik SJ, Goodpaster BH, Kelley DE et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity 2010; 18: 1695-700.
49. Kalhan SC, Guo L, Edmison J et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011; 60: 404-13.
50. Yamakado M, Tanaka T, Nagao K et al. Plasma amino acid profile is associated with visceral fat accumulation in obese Japanese subjects. Clin Obes 2012; 2: 29-40.
51. Hanamatsu H, Ohnishi S, Sakai S et al. Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. Nutr Diabetes 2014; 4: e141.
52. Schlitt A, Blankenberg S, Yan D et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab 2006; 3: 5.
53. Anjani K, Lhomme M, Sokolovska N et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J Hepatol 2015; 62: 905-12.
54. Jacobs RL, van der Veen JN, Vance DE. Finding the balance: the role of S-adenosylmethionine and phosphatidylcholine metabolism in development of nonalcoholic fatty liver disease. Hepatology 2013; 58: 1207-9.
55. Garcia-Ruiz C, Mato JM, Vance D et al. Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways. J Hepatol 2015; 62: 219-33.